Therapeutic vaccination with a trivalent T-cell receptor (TCR) peptide vaccine restores deficient FoxP3 expression and TCR recognition in subjects with multiple sclerosis

Immunology

Volumn 123, Issue 1, 2008, Pages 66-78

  Vandenbark, Arthur A ^a,b   Culbertson, Nicole E ^b   Bartholomew, Richard M ^c   Huan, Jianya ^b   Agotsch, Marci ^a   LaTocha, Dorian ^a   Yadav, Vijayshree ^a,b   Mass, Michele ^b   Whitham, Ruth ^a,b   Lovera, Jesus ^a,b   Milano, June ^c   Theofan, Georgia ^c   Chou, Yuan K ^b   Offner, Halina ^a,b   Bourdette, Dennis N ^a,b  

^a PORTLAND VA MEDICAL CENTER   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c Orchestra Therapeutics Inc   (United States)

Author keywords

FoxP3 expression; Immunoregulation; Multiple sclerosis; T cell receptor; Vaccine

Indexed keywords

FREUND ADJUVANT; INTERLEUKIN 10; NEUROVAX; PEPTIDE; T LYMPHOCYTE RECEPTOR; TRANSCRIPTION FACTOR FOXP3; TRIPLE VACCINE; TRIVALENT PEPTIDE VACCINE; UNCLASSIFIED DRUG; VACCINE;

ADULT; AGED; ARTICLE; AUTOIMMUNE DISEASE; CD4+ CD25+ T LYMPHOCYTE; COMPLEMENTARITY DETERMINING REGION; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; HUMAN; IMMUNOREGULATION; INFLAMMATION; MALE; MULTIPLE SCLEROSIS; PARAMETER; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; TREATMENT OUTCOME; VACCINATION;

ADULT; AGED; AUTOANTIGENS; AUTOIMMUNITY; COMPLEMENTARITY DETERMINING REGIONS; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; GENES, T-CELL RECEPTOR; HUMANS; IMMUNE TOLERANCE; IMMUNOLOGIC MEMORY; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; NERVE TISSUE PROTEINS; RECEPTORS, ANTIGEN, T-CELL; T-LYMPHOCYTES, REGULATORY; VACCINATION; VACCINES, SUBUNIT;

EID: 37149039794     PISSN: 00192805     EISSN: 13652567     Source Type: Journal    
DOI: 10.1111/j.1365-2567.2007.02703.x     Document Type: Article

References (52)

1. Bielekova B, Sung M-H, Kadom N, Simon R, McFarland H, Martin R. Expansion and functional relevance of high-avidity myelin-specific CD4+ T cells in multiple sclerosis. J Immunol 2004 172 : 3893 904.
2. Lunemann JD, Ruckert S, Kern F, Wendling U, vanderZee R, Volk HD, Zipp F. Cross-sectional and longitudinal analysis of myelin-reactive T cells in patients with multiple sclerosis. J Neurol 2004 251 : 1111 20.
3. Vandenbark AA, Finn T, Barnes D et al. Diminished frequency of IL-10 secreting, TCR peptide-reactive T-cells in multiple sclerosis patients may allow expansion of activated memory T-cells bearing the cognate BV gene. J Neurosci Res 2001 66 : 171 6.
4. Astier AL, Meiffren G, Freeman S, Hafler DA. Alterations in CD46-mediated Tr1 regulatory T cells in patients with multiple sclerosis. J Clin Invest 2006 116 : 3252 7.
5. Viglietta V, Baecher-Allan C, Weiner HL, Hafler DA. Loss of functional suppression by CD4+CD25+ regulatory T cells in patients with multiple sclerosis. J Exp Med 2004 199 : 971 9.
6. Huan J, Culbertson N, Spencer L et al. Decreased FoxP3 levels in multiple sclerosis patients. J Neurosci Res 2005 81 : 45 52.
7. Antel J, Bania M, Noronha A, Neely S. Defective suppressor cell function mediated by T8+ cell lines from patients with progressive multiple sclerosis. J Immunol 1986 137 : 3436 9.
8. Feldmann M, Steinman L. Design of effective immunotherapy for human autoimmunity. Nature 2005 435 : 612 9.
9. Vandenbark AA. TCR peptide vaccination in multiple sclerosis: Boosting a deficient regulatory network that may involve TCR-specific CD4+CD25+ Treg cells. Curr Drug Targets - Inflamm Allergy 2005 4 : 85 94.
10. Vandenbark AA, Culbertson NE. Trivalent T cell receptor peptide vaccine for treatment of multiple sclerosis targets predominant V genes widely implicated in autoimmune diseases and allergy. In : Zhang J, ed. Immune Regulation and Immunotherapy in Autoimmune Disease. New York, NY : Springer Life Sciences, 2007 : 369 8.
11. Bourdette DN, Edmonds E, Smith C et al. A highly immunogenic trivalent T cell receptor peptide vaccine for multiple sclerosis. Multiple Sclerosis 2005 11 : 552 61.
12. Vandenbark AA, Chou YK, Whitham R et al. Treatment of multiple sclerosis with T cell receptor peptides: Results of a double-blind pilot trial. Nature Med 1996 2 : 1109 15.
13. Vandenbark AA, Morgan E, Bourdette D et al. TCR peptide therapy in human autoimmune diseases. Neurochem Res 2001 26 : 713 30.
14. Pender MP, Csurhes PA, Greer JM et al. Surges of increased T cell reactivity to an encephalitogenic region of myelin proteolipid protein occur more often in patients with multiple sclerosis than in healthy subjects. J Immunol 2000 165 : 5322 31.
15. Hellings N, Baree M, Verhoeven C, D'hooghe MB, Medaer R, Bernard CC, Raus J, Stinissen P. T-cell reactivity to multiple myelin antigens in multiple sclerosis patients and healthy controls. J Neurosci Res 2001 63 : 290 302.
16. Buenafe AC, Tsaknaridis LJ, Spencer L et al. Specificity of regulatory CD4+CD25+ T cells for self-T cell receptor determinants. J Neurosci Res 2004 76 : 129 40.
17. Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor α-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 1995 155 : 1151 64.
18. Shevach EM. Regulatory T cells in autoimmunity. Ann Rev Immunol 2000 18 : 423 49.
19. Curiel TJ. Regulatory T-cell development: Is FoxP3 the decider? Nature Med 2007 13 : 250 3.
20. Wan YY, Flavell RA. Regulatory T-cell functions are subverted and converted owing to attenuated FoxP3 expression. Nature 2007 445 : 766 70.
21. Wu Y, Borde M, Heissmeyer V et al. FoxP3 controls regulatory T cell function through cooperation with NFAT. Cell 2006 126 : 375 87.
22. Cabarrocas J, Cassan C, Magnusson F et al. FoxP3+CD25+ regulatory T cells specific for a neo-self-antigen develop at the double-positive thymic stage. Proc Natl Acad Sci USA 2006 103 : 8453 8.
23. Sakaguchi S. Naturally arising FoxP3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self. Nat Immunol 2005 6 : 345 52.
24. Lim HW, Hillsamer P, Banham AH, Kim CH. Cutting Edge. Direct suppression of B cells by CD4+CD25+ regulatory T cells. J Immunol 2005 175 : 4180 3.
25. Ghiringhelli F, Menard C, Terme M et al. CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor-beta-dependent manner. J Exp Med 2005 202 : 1075 85.
26. Tadokoro CE, Shakhar G, Shen S, Ding Y, Lino AC, Maraver A, Lafaille JJ, Dustin ML. Regulatory T cells inhibit stable contacts between CD4+ T cells and dendritic cells in vivo. J Exp Med 2006 203 : 505 11.
27. Sakaguchi S. Regulatory T cells: Key controllers of immunological self-tolerance. Cell 2000 101 : 455 8.
28. Walker LSK, Chodos A, Abbas AK. Antigen-dependent proliferation of CD4+CD25+ regulatory T cells in vivo. J Exp Med 2003 198 : 249 58.
29. Walker MR, Carson BD, Nepom GT, Ziegler SF, Buckner JH. Do novo generation of antigen specific CD4+CD25+ regulatory T cells from human CD4+CD25- cells. Proc Natl Acad Sci USA 2005 102 : 4103 8.
30. Reddy J, Illes Z, Zhang X et al. Myelin proteolipid protein- specific CD4+CD25+ regulatory cells mediate genetic resistance to experimental autoimmune encephalomyelitis. Proc Natl Acad Sci USA 2004 101 : 15434 9.
31. Yu P, Gregg RK, Bell JJ et al. Specific T regulatory cells display broad suppressive functions against experimental allergic encephalomyelitis upon activation with cognate antigen. J Immunol 2005 174 : 6772 80.
32. Ochoa-Raparaz J, Riccardi C, Rynda A, Jun S, Callis G, Pascual DW. Regulatory T cell vaccination without autoantigen protects against experimental autoimmune encephalomyelitis. J Immunol 2007 178 : 1791 9.
33. Gavin MA, Torgerson TR, Houston E et al. Single-cell analysis of normal and FoxP3-mutant human T cells: FoxP3 expression without regulatory T cell development. Proc Nat Acad Sci USA 2006 103 : 6659 64.
34. Nicolson KS, O'Neill EJ, Sundstedt A, Streeter HB, Minaee S, Wraith DC. Antigen-induced IL-10+ regulatory T cells are independent of CD25+ regulatory cells for their growth, differentiation, and function. J Immunol 2006 176 : 5329 37.
35. Poser CM, Paty DW, Scheinberg L et al. New diagnostic criteria for multiple sclerosis: Guidelines for research protocols. Ann Neurol 1983 13 : 227 31.
36. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: Results of an international survey. Neurology 1996 46 : 907 11.
37. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an Expanded Disability Status Scale (EDSS). Neurology 1983 33 : 1444 52.
38. Taswell C. Limiting dilution assays for the determination of immunocompetent cell frequencies. I. Data analysis. J Immunol 1981 26 : 1614.
39. Vandenbark AA, Culbertson N, Finn T et al. Human TCR as antigen: Homologies and potentially cross-reactive HLA-DR2-restricted epitopes within the AV and BV CDR2 loops. Crit Rev Immunol 2000 20 : 57 83.
40. Jordan MS, Boesteanu A, Reed AJ, Petrone AL, Hoelenbeck AE, Lerman MA, Naji A, Caton AJ. Thymic selection of CD4+CD25+ regulatory T cells induced by an agonist self- peptide. Nature Immunol 2001 2 : 301 6.
41. Cohen IR, Young DB. Autoimmunity, microbial immunity and the immunological homunculus. Immunol Today 1991 12 : 105 10.
42. Vandenbark AA, Hashim GA, Offner H. T cell receptor peptides in treatment of autoimmune disease: rationale and potential. J Neurosci Res 1996 43 : 391 402.
43. Jiang H, Sercarz E, Nitecki D, Pernis B. The problem of presentation of T cell receptor peptides by activated T cells. Ann N Y Acad Sci 1991 636 : 28 32.
44. Vandenbark AA, Chou YK, Bourdette DN, Whitham R, Offner H. Immunogenicity is critical to the therapeutic application of T cell receptor peptide. Drug News Persp 1997 10 : 341 6.
45. Antel J, Brown M, Nicholas MK, Blain M, Noronha A, Reder A. Activated suppressor cell function in multiple scleoris - clinical correlations. J Neuroimmunol 1988 17 : 323 30.
46. Venken K, Hellings N, Hensen K et al. Secondary progressive in contrast to relapsing-remitting multiple sclerosis patients show a normal CD4+CD25+ regulatory T-cell function and FoxP3 expression. J Neurosci Res 2006 83 : 1432 46.
47. Hong J, Li N, Zhang X, Zheng B, Zhang JZ. Induction of CD4+CD25+ regulatory T cells by copolymer-1 through activation of transcription factor FoxP3. Proc Natl Acad Sci USA 2005 102 : 6449 54.
48. Hong J, Zang YCQ, Nie H, Zhang JZ. CD4+ regulatory T cell responses induced by T cell vaccination in patients with multiple sclerosis. Proc Natl Acad Sci USA 2006 103 : 5024 9.
49. Mantel P-Y, Ouaked N, Ruckert B, Karagiannidis C, Welz R, Blaser K, Schmidt-Weber CB. Molecular mechanisms underlying FoxP3 induction in human T cells. J Immunol 2006 176 : 3593 602.
50. Allegretta M, Nicklas JA, Sriram S, Albertini RJ. T cells responsive to myelin basic protein in patients with multiple sclerosis. Science 1990 247 : 718 21.
51. Lodge PA, Allegretta M, Steinman L, Sriram S. Myelin basic protein peptide specificity and T-cell receptor gene usage of HPRT mutant T-cell clones in patients with multiple sclerosis. Ann Neurol 1994 36 : 734 40.
52. Deaglio S, Dwyer KM, Gao W et al. Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediated immune suppression. J Exp Med 2007 204 : 1257 65.